Peer-reviewed veterinary case report
Anti-ICOS antibody treatment for chronic graft-versus-host disease
By Graves, Scott S et al.·Published in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2018·Transplantation Biology Program, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Anti-Inducible Costimulator Monoclonal Antibody Treatment of Canine Chronic Graft-versus-Host Disease.
- Species:
- dog
Plain-English summary
Five dogs developed chronic graft-versus-host disease (GVHD) after receiving stem cell transplants from unrelated donors. They were treated with a medication called anti-ICOS monoclonal antibody, which was given in three doses over a short period. While one dog did not respond and unfortunately passed away, the other dogs that received the treatment lived significantly longer after their GVHD diagnosis compared to those that did not receive the medication. This suggests that anti-ICOS therapy could be a helpful option for dogs suffering from chronic GVHD.
People also search for: dog graft-versus-host disease treatment · canine chronic GVHD symptoms · stem cell transplant dog care
Abstract
In murine model systems inducible costimulator (ICOS) signaling has been implicated in the formation of chronic graft-versus-host disease (GVHD). Previously, we showed that chronic GVHD can be reproducibly produced in the dog hematopoietic cell transplantation (HCT) model and that ICOS expression is upregulated on T cells in dogs with chronic GVHD. The goal of the present study was to determine whether administration of a short course of anti-canine ICOS mAb could alter the rapid and progressive course of chronic GVHD. Five dogs underwent HCT from dog leukocyte antigen mismatched unrelated donors after total body irradiation. Postgrafting immunosuppression consisted of methotrexate (days 1, 3, 6, and 11) and cyclosporine (days -1 through 78). Anti-ICOS mAb (3 injections, 72 hours apart) was administered upon diagnosis of GVHD. One dog failed to respond to anti-ICOS mAb therapy and succumbed to chronic GVHD in a time course similar to control untreated dogs. Overall, anti-ICOS-treated dogs experienced a significant prolongation in survival from the time of diagnosis of chronic GVHD compared with control dogs. Within the limitations of the number of study dogs we suggest that a short course of anti-ICOS mAb may be useful in the treatment of chronic canine GVHD.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/28958896/